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In Australia, alcohol is consumed by nearly 80% of the population1 and is responsible for 4.6% of the burden of disease.2 The 
Australian guidelines to reduce harms from 
alcohol suggest that, to prevent chronic harm 
from alcohol consumption, intake should 
be restricted to no more than two standard 
drinks per day on average and to prevent 
acute harms, no more than four drinks on 
any single occasion, with a standard drink 
being defined as containing 10g of alcohol.3 
However, in the most recent national health 
survey, 16% of Australians reported that they 
exceeded the first chronic harm guideline in 
the preceding year.1 Previous studies have 
suggested that alcohol is consumed by 
people with diagnosed chronic disease at 
similar rates to the general population.4 Given 
that chronic disease is identified as the major 
contributor to disease burden in Australia,2 
the intersection of these two prevalent 
sources of morbidity is potentially important. 
In Townsville, a regional city of Queensland, 
Australia, general practitioners have identified 
concerns about managing excess alcohol 
consumption in patients with chronic 
disease.5 This is complicated by higher rates 
of alcohol consumption than the national 
average,6 limited specialist drug and alcohol 
services5,7 and perceived lack of resources 
and referral options.5 This concern has been 
echoed by general practitioners elsewhere,8 
suggesting that it may be an issue for 
practitioners more widely. 
Chronic disease management requires 
close collaboration between the health 
practitioner and the patient to successfully 
prevent complications and slow progression 
of the disease.9 This essential collaboration 
between patient and health practitioner is 
potentially inhibited by alcohol consumption, 
which has been associated with poorer 
adherence to chronic disease-related self-
care behaviours10,11 as well as decreased 
practitioner motivation to engage with 
patients who are drinking to excess.5,8 While 
there are limited studies on the reasons 
for this decrease in self-care and health-
related behaviours and awareness, it has 
been demonstrated across a wide range of 
demographics in those with and without 
chronic disease.12,13 
While both acute and chronic consumption 
of alcohol can be harmful,3 the focus of this 
study was on chronic consumption above 
Australian guidelines, as this was felt to be 
most likely to reflect on chronic disease 
clinical outcomes, which are the accumulation 
of small gains or losses over extended time 
periods.14 Alcohol consumption has the 
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Abstract
Objective: To better understand the impact of alcohol consumption on the clinical 
management of chronic diseases in a regional general practice setting.
Methods: A retrospective chart audit was undertaken of individual patient records at two 
large group general practices in Townsville, a regional Australian city. Three common indicator 
chronic diseases were selected that have clear management guidelines for general practice: 
type 2 diabetes; chronic obstructive pulmonary disease; and chronic kidney disease. The audits 
were analysed using SPSS software to examine the association between alcohol consumption 
on acquisition of clinical management targets and primary disease intermediate outcomes 
(haemoglobin A1c fraction; per cent of normal forced expiratory volume at one second; and 
estimated glomerular filtration rate).
Results: A total of 457 records were audited. Higher-risk alcohol consumption is associated 
with reduced ability of patients to reach management targets (F[3,453]=3.68; p=0.012) and 
decreased standardised primary disease outcome (F[3,403]=2.86; p=0.037).
Conclusion: Higher-risk alcohol consumption is associated with reduced attainment of chronic 
disease management targets and worse chronic disease outcomes. 
Implications for public health: Alcohol consumption should be assessed frequently in people 
with chronic disease, especially when there is difficulty acquiring management targets or 
worsening of disease outcomes without a clear explanation. Better education about the 
potential associations between alcohol use and chronic disease would benefit those managing 
these complex conditions, both clinicians and patients.
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potential to affect both the behavioural 
and physiological factors contributing to 
chronic disease,12,14 both directly and via 
contributions to mental health challenges.15 
This research investigates the association 
between alcohol on the attainment of clinical 
practice guideline-based management goals 
and clinical outcomes of chronic disease in 
the general practice setting in regional north 
Queensland, where concerns about the issue 
have been raised.5 
Methods
A retrospective chart audit was conducted 
at two large group general practices in 
Townsville, purposively selected to cover a 
broad geographical and demographic section 
and to maximize the sampling of potential 
clients. The collection period was twelve 
months (1 January 2015–31 December 2015) 
with data extraction undertaken between 
February 2016 and February 2017. Three 
indicator chronic diseases were chosen that 
were common and had clear evidence-based 
management guidelines for general practice: 
type 2 diabetes mellitus (T2DM),16 chronic 
obstructive pulmonary disease (COPD)17 and 
chronic kidney disease (CKD).18 
Ethics approval was obtained from the 
James Cook University Human Research 
Ethics Committee [H6279]. Informed consent 
was obtained at the practice level with 
advertisements placed in the practice to 
allow people the option to request that their 
records not be included in the study. This was 
in addition to existing practice level consent 
for the use of records for quality improvement 
and clinical auditing purposes. Information 
sheets were made available through the 
chronic disease nurse for people who wanted 
further information; the chronic disease 
nurses and the general practitioners (GPs) 
also discussed the project with any client they 
felt may have been unable to read or interpret 
the information.
The chart audit was undertaken by a 
registered medical practitioner (JM), who 
did not work at either clinical practice, using 
a minimally intrusive approach. All records 
accessed were electronic. The key word 
and function searches within the software 
were used to find data to avoid unnecessary 
reading of patient consultation details. 
The eligible case list was cross-checked 
with the chronic disease nurse’s database 
of active chronic disease patients to check 
completeness and maximise the number of 
eligible records. No identifying details were 
collected. A temporary record number was 
included to enable identification of duplicate 
records and deleted on completion of 
collection. To generate the patient list at each 
practice the electronic software was searched, 
as diagnosis and keyword, for the three 
indicator chronic diseases (T2DM, COPD and 
CKD), looking for records active (at least one 
visit) in the retrospective collection timeframe 
(2015). The generated list was verified by 
the chronic disease nurse at each practice. 
Patient lists were kept secured at the practice 
during collection and were destroyed at the 
completion of collection. No identifiable 
information left the practice.
Data (Box 1) from every second record were 
collected for T2DM and COPD, and due to 
lower patient numbers, all CKD records were 
considered. Records were first checked for 
exclusion criteria: no information regarding 
alcohol consumption; no evidence to 
support the presence of the chronic disease; 
evidence of the patient transferring into 
or out of the practice during the collection 
timeframe; no attendances recorded in the 
allotted timeframe or on ethical grounds 
(patient was known to the researcher). All 
records that were excluded due to no alcohol 
consumption data were incomplete;  most 
commonly they related to a single visit from a 
person from out of area. 
Management targets
The management targets for each disease 
were derived from the relevant guideline.16-18 
The number of targets acquired was divided 
by the total number of targets for that disease 
and expressed as a percentage to enable 
comparisons between diseases.
The management targets were: 
•	 COPD: no smoking, spirometry within 12 
months, influenza vaccination within 12 
months, four or more visits per year.
•	 T2DM: BMI<25 kg/m2, HbA1c< 53 mmol/
mol, lipids in range (TC<4 mol/L, HDL>1 
mol/L, LDL<2 mol/L), systolic BP<140 
mmHg, influenza vaccination within 12 
months, four or more visits per year, allied 
health involvement in 12 months, no 
smoking.
•	 CKD: Lipids in range, systolic BP<130 
mmHg, ACR or PCR within 12 months, Hb 
>100 g/L, influenza vaccination within 12 
months, four or more visits per year.
Classification of severity
COPD: assigned by spirometry (FEV1 % 
predicted) or specialist determination if 
unable to do spirometry.
•	 Mild: 60+% predicted.
•	 Moderate: 41-59% predicted. 
•	 Severe: <40% predicted.
CKD: assigned by eGFR or formal GFR 
measurement where available. 
•	 Mild: eGFR > 60 + microalbuminuria or 
eGFR 45-59. 
•	 Moderate: eGFR 30-59+ microalbuminuria 
or eGFR 30-44 with no albuminuria. 
•	 Severe: eGFR < 30 or macroalbuminuria. 
T2DM: severity was assigned by a 
combination of number of medications and 
HbA1c as per Box 2.
Assessment of alcohol consumption
Alcohol consumption was assessed using 
the Alcohol Use Disorders Identification 
Test – Consumption (AUDIT-C) tool19 (Box 
3), as this was embedded into the practice 
software used at both practices and was 
therefore the most consistent and reliable 
method of measuring alcohol consumption. 
For each patient, this was confirmed by using 
Box 1: Data points collected.
All conditions Diagnosis, age, sex, Indigenous identification, medications, number of doctor visits, alcohol use (frequency, 
amount, frequency of >6 drinks), smoking status, and current influenza vaccination.
T2DM Body mass index (BMI), last podiatry recorded, last optometry recorded, glycated haemoglobin fraction 
(HbA1c), total cholesterol (TC), low density lipoprotein (LDL), high density lipoprotein (HDL), last recorded 
systolic blood pressure (BP)
COPD Date of last spirometry, forced expiratory volume-one second % predicted (FEV1 %), disease severity as 
determined by specialist (if unable to complete spirometry)
CKD BMI, albumin creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), haemoglobin (Hb), TC, LDL, 
HDL, systolic BP





0-1 Mild Mild Severe
2 Moderate Moderate Severe
3+ Moderate Severe Severe
Insulin Severe Severe Severe
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a keyword search to look for evidence of 
alcohol assessment in the written notes. 
As the AUDIT-C was being used as a proxy 
for consumption rather than a screening 
tool for dependence, five categories were 
considered to give the broadest range of 
potential results: score 0 (non-drinkers), 
score 1–4 (low-risk drinkers), score 5–8 
(moderate-risk drinkers) and score 9+ (higher 
risk drinkers). A small number of people 
(n=10) who had an episodic-only heavy 
alcohol consumption pattern in the absence 
of regular consumption (less than monthly 
consumption of more than six drinks) 
and those with insufficient information to 
generate an AUDIT-C score (n=15) were 
excluded from the analysis, leaving 457 
records.
Assessment of smoking 
While the practice records recorded current, 
past (amount, duration and length of 
abstinence) or never smoked, due to the low 
group numbers only current smoking (yes/
no) could be assessed and this is reported in 
Table 2.
Disease outcomes
The study used widely accepted markers of 
disease activity for the individual diseases: 
eGFR for CKD, FEV1% for COPD and HbA1c 
for T2DM. To increase the available sample 
size sufficiently to consider the impact of 
co-variables, the primary outcome was 
expressed as a percentage of the value 
obtained in an unaffected individual. The 
value that would be considered non-
diagnostic (100% for FEV1%, 90 for eGFR and 
31mmol/mol for HbA1c) was set as 100% and 
the worst outcome measure obtained was 
set at 0%. This value was termed % standard 
outcome.
Analysis
Statistical analyses were completed using 
SPSS Statistics 25.20 Between-group 
comparisons of the AUDIT-C categories were 
made using independent samples t-tests or 
ANOVA for numerical variables. Where ANOVA 
was used, Bonferroni post hoc analyses were 
also completed. Categorical variables were 
analysed with chi-square tests and Fisher’s 
exact tests where assumptions were violated. 
Analysis of covariance was then undertaken 
to assess the association between AUDIT-C 
score on each outcome measure (mean per 
cent management targets reached, mean 
per cent standardised disease outcome), 
adjusting for potential confounders: age, sex, 
Indigenous identification status, diagnosis, 
disease severity category and current 
smoking status. Those demographic factors 
that were identified to be associated with 
both AUDIT-C score and the disease outcome 
measures were included as covariates. 
Results
Data collection
Records were obtained from two large 
group practices with a combined client 
base of 19,704 or 11% of the total Townsville 
population, with 63% (12 377) of the 
client pool having been seen during the 
collection period. From these records, 482 
patients were audited from a pool of 1,179 
patients identified with T2DM, COPD or CKD 
(combined practice prevalence of 9.5%; Table 
1). The data collected are summarised in  
Table 2. 
Alcohol consumption: relationship to 
sample demographics
The associations between alcohol 
consumption as measured by AUDIT-C score 
and sample characteristics are shown in Table 
2. Two demographic factors were significantly 
associated with AUDIT-C score category: sex 
(X2(3)=28.40; p<0.001) and current smoking 
status (X2(3)=32.19; p<0.001). AUDIT-C score 
category was not associated with chronic 
disease diagnosis (X2(6)=9.03; p=0.172), 
age (X2(6)=4.21; p=0.650), Indigenous 
identification (X2(3)=7.52; p=0.057) or disease 
severity (X2(6)=8.30; p=0.217). 
The association between alcohol 
consumption and management 
targets
As shown in Figure 1, the mean percentage 
of management targets reached differed 
by AUDIT-C category (F[3,453]=3.68; 
p=0.012). Specifically, mean percentage 
of management targets reached was 
significantly lower in participants who 
scored AUDIT-C 9+ than in participants 
who scored AUDIT-C 5-8 (p=0.03), AUDIT-C 
1-4 (p=0.01) and AUDIT-C 0 (p=0.04). As 
expected, attainment of management targets 
was positively correlated with standardised 
outcome (r=0.29; p=0.01). 
Having established an association between 
alcohol consumption and management 
targets, analysis of covariance was performed 
to investigate contributing effects. Smoking 
could not be assessed as a covariate as 
non-smoking was a management target for 
all three chronic diseases, therefore the only 
variable adjusted for was sex. Differences 
between AUDIT-C groups and mean 
percentage management targets achieved 
remained after adjustment for sex (F(3, 
453)=3.14; p=0.025). 
Box 3: AUDIT-C.
Q1: How often do you have a drink containing alcohol?
Never (0) ≤ monthly (1) 2-4 /month (2) 2-3 / week (3) 4+ / week (4)
Q2: How many standard drinks do you have on a typical drinking day?
1-2 (0) 3-4 (1) 5-6 (2) 7-9 (3) 10+ (4)
Q3: How often do you have 6 or more standard drinks?
Never (0) ≤ monthly (1) Monthly (2) Weekly (3) Almost daily (4)
Table 1: Records collected and exclusions.
T2DM COPD CKD All
Number of records identified 644 385 150 1,179
Exclusions
Record incomplete 86 32 41 159
Disease evidence lacking 30 40 47 117
Ethical 1 0 1 2
Total exclusions 117 72 89 278
Total eligible 527 313 61 901
Sampling method 1 in 2 1 in 2 All valid
Records collected 263 158 61 482
Post collection exclusion 
(insufficient alcohol data)
17 4 4 25
Final record count 246 154 57 457
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consumption and disease outcomes
Mean standardised disease outcome 
percentage differed significantly by AUDIT-C 
category (F(3,403)=2.86; p=0.037; see Figure 
2). There were no significant between-group 
differences in post- hoc analysis, likely due 
to the low number of observations in some 
categories, but participants in the AUDIT-C 9+ 
category had the lowest mean standardised 
disease outcome (62.2), and the highest 
was in the AUDIT-C 1-4 category (72.6). The 
association remained after adjusting for sex 
and current smoking status (F(3, 403)=2.87; 
p=0.04). 
Discussion
Overall, alcohol had a measurable association 
with the management of chronic disease 
across both domains studied (reaching 
management targets and standardised 
primary outcome). In general, increased 
alcohol use was associated with reduced 
mean per cent of management targets 
reached and worse standardised primary 
disease outcomes. 
Alcohol consumption patterns
AUDIT-C was originally intended and verified 
as a screening tool for alcohol dependence 
and alcohol-related harm, rather than as 
a stand-alone measure of consumption; 
however, it performs well in detecting 
hazardous drinking.21 All AUDIT-C scores 
were verified by checking the written notes. 
Consumption in participants who scored 
nine or more ranged from 5–6 drinks, 4+ 
days/week with 6 or more weekly to 10+ 
drinks per day. AUDIT–C scores higher than 
five are consistent with drinking in excess of 
Australian alcohol consumption guidelines, 
with scores of four equivocal. Using a cutoff 
of five, rather than the more commonly used 
four, lowers the sensitivity for detecting 
hazardous alcohol consumption but raises 
the specificity.21 Furthermore, it better aligns 
with the Australian guidelines that were in 
use at the time of the data collection, as many 
participants who scored four reported daily 
drinking of 1–2 standard drinks. Based on 
this, 30% of the patients in this study were 
drinking above the regular consumption 
guideline, compared with 17% of the general 
Australian population in 2015.1 This rate 
was higher in patients with COPD (39%). 
Abstinence rates of the sample were 40%, 




0 1-4 5-8 9+
Number of records 198 158 58 43 457
Age in years, n (%)
 <50 15 (41%) 14 (38%) 6 (16%) 2 (5%) 37 (100%)
 50-75 127 (44%) 95 (33%) 40 (14%) 27 (9%) 289 (100%)
 >75 56 (42%) 49 (37%) 12 (9%) 14 (11%) 131 (100%)
Sex, n (%)
 Male 77 (33%) 80 (35%) 40 (17%) 32 (14%) 229 (100%)
 Female 121 (53%) 78 (34%) 18 (8%) 11 (5%) 228 (100%)
Identification, n (%) 
 Aboriginal &/or Torres Strait Islander 48 (57%) 21 (25%) 7 (8%) 8 (10%) 84 (100%)
 Non-Indigenous 151 (42%) 133 (37%) 46 (37%) 31 (9%) 361 (100%)
 Missing n=12
Current smoking, n (%)
 Yes 41 (41%) 20 (20%) 18 (18%) 22 (22%) 101 (100%)
 No 157 (44%) 138 (39%) 40 (11%) 21 (6%) 356 (100%)
Diagnosis, n (%)
 T2DM 110 (45%) 87 (35%) 30 (12%) 19 (8%) 246 (100%)
 COPD 61 (40%) 47 (30%) 24 (16%) 22 (14%) 154 (100%)
 CKD 27 (47%) 24 (42%) 4 (7%) 2 (4%) 57 (100%)
Severity category, n (%)
 Mild 79 (40%) 70 (35%) 29 (15%) 20 (10%) 198 (100%)
 Moderate 78 (44%) 63 (36%) 23 (13%) 12 (7%) 176 (100%)
 Severe 41 (49%) 25 (30%) 6 (7%) 11 (13%) 83 (100%)
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which is substantially higher than the general 
Australian population (19.4%).1 The reason 
for the higher abstinence rate cannot be 
definitively determined from this sample but 
likely reflects an alteration in risk behaviours 
as a result of their chronic disease diagnosis 
on the recommendation of their doctor.14 
This sample also contains a high proportion 
of people with T2DM, which has been 
associated with higher than normal alcohol 
abstinence rates in some studies.22 
Generalisability of the findings
The overall proportion of people with COPD 
and T2DM reflects the proportions in the 
Australian population.1 The proportion for 
CKD is substantially lower than anticipated by 
national rates, especially in the mild range. It 
is possible that a proportion of the excluded 
CKD records, where insufficient evidence was 
available to support the diagnosis (47/150), 
would have met mild CKD criteria, but in 
the absence of overt clinical illness, this was 
not being closely monitored at the time and 
hence there was no evidence in the patient’s 
record. 
The total patient pool in this study was 
more than 12,000, which equates to 7% of 
the population in Townsville. Hence, this 
sample is likely to be representative of the 
Townsville chronic disease population who 
seek medical treatment. Comparison of the 
demographics of the T2DM sample with a 
national diabetes audit sample of more than 
5,000 people showed similar means and 
overlapping ranges for age, sex distribution, 
blood pressure readings, lipid levels and 
HbA1c,23 suggesting that the findings are 
likely to be generalisable to the Australian 
chronic disease population with respect to 
these characteristics. The Townsville sample 
had a higher representation of people who 
identified as Aboriginal or Torres Strait 
Islander, a reflection of higher than national 
average percentage locally.6 The national 
audit sample, while very comprehensive in 
many regards, did not include information 
about alcohol consumption.23 
Alcohol association with 
management targets
The key finding of decreased attainment 
of management targets associated 
with increased alcohol consumption is 
consistent with other literature looking 
at the relationship between alcohol on 
self-care behaviours.10,24 The ability to meet 
management targets is a complex interplay 
between physician or practice-led initiatives 
and individual health behaviours, including 
the person’s self-efficacy to initiate changes. 
While self-care behaviours are integral to 
chronic disease management, there is also 
evidence that clinicians are less inclined to 
engage with people who are drinking to 
excess.5,8 This study does not distinguish the 
stage or stages of the management pathway 
that are being impacted. It does, however, 
suggest that if a patient is not meeting 
management targets, alcohol consumption 
is one of the areas that may need to be more 
thoroughly assessed. 
The impact of smoking could not be 
independently assessed as ‘not smoking’ was 
a management target for all three chronic 
diseases. 
Association of alcohol consumption 
with disease outcomes
As chronic diseases are generally progressive, 
many factors impact on disease outcome. 
Throughout the literature, evidence of the 
impact of alcohol on disease outcomes varies 
considerably and is complicated by data 
collection and coding issues. In this study, 
there was a small but measurable association 
between alcohol consumption and disease 
outcomes above and beyond the effects of 
demographics with independent associations 
with both outcome variables. Due to the 
small effect, demonstrating the difference 
within single disease cohorts was more 
problematic and may well be the domain of 
large national audits. 
This study used a primary disease outcome 
that was readily available in most records and 
reflected guidance to GPs about monitoring 
of that disease. FEV1 % predicted and GFR 
are well-established markers of disease 
progression. HbA1c monitors glucose control 
over a three-month period and is therefore 
a less sensitive measure of progression of 
disease. However, it is well associated with 
adverse outcomes of diabetes and is widely 
used and accepted in the literature.25 More 
accurate markers for diabetes, such as HbA1c 
trends or disease complications, were not 
able to be consistently obtained from the 
records without overly obtrusive inspection. 
Limitations
Practice data are designed for clinical care 
of individuals, not for research. Not all data 
that would have been useful for this study 
were available or searchable. For example, 
letters stored as scanned documents are not 
generally searchable. The data were collected 
as entered in the practice records, however, 
where possible, verification was sought from 
the consultation notes. These limitations are 
offset by clear inclusion criteria, consistency 
of collection and a sample size that exceeded 
the minimum 360 records suggested by 
sample size calculations. 
While the data come from only two practices 
in one regional city in north Queensland, 
Australia, the sample covers the practice 
of more than twenty doctors and 7% of 
the population of that city. The pool of 
patients from which the sample is collected 
is socioeconomically and geographically 
distributed across the town, increasing 
the likelihood that it is representative. The 
similarity in demographic and clinical data 
with large national samples increases the 
generalisability of the findings. 
Alcohol consumption is measured by 
AUDIT-C, which is collected at a point in time. 
Unlike smoking status, which is routinely 
recorded as current smoker, ex-smoker or 
never smoked, alcohol consumption was 
routinely recorded in the software as a single 
entry. Not all records distinguished between 
recent ex-drinkers, long-term ex-drinkers 
or those who never drank alcohol. Recent 
substantial changes in alcohol consumption 
may not be reflected. This means that the 
AUDIT-C ‘0’ category needs to be interpreted 
with caution. 
Conclusions
In this study, increased alcohol consumption 
was associated with a reduced ability to meet 
management targets for chronic disease 
and with poorer disease outcomes. It is 
recommended that clear advice on alcohol 
assessment and management should be 
included in all chronic disease management 
guidelines. Higher-risk alcohol consumption 
should routinely be further explored in 
patients living with chronic disease who 
demonstrate an inability to meet targets in 
management guidelines, and as a potential 
contributor to unexplained poor outcomes. 
The modification of practice software to 
better monitor alcohol use over time could 
assist GPs in this task. 
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